Headquarters: Suffern, New York, USA
Founded: 1997
Founder(s): Drore Eisen, Mark Rutenberg, William Huffnagle
Notable Investors:
CDx Diagnostics is a healthcare company that specializes in the development and commercialization of innovative diagnostic technologies for the early detection and diagnosis of cancer. The company’s flagship product is the WATS3D biopsy, which is designed to improve the accuracy and effectiveness of cancer screening and diagnosis. It has been applied to the detection of cancer in the esophagus, stomach, and colon, as well as pre-cancerous conditions.
The WATS3D biopsy is a minimally invasive procedure that uses a brush to collect a larger tissue sample than traditional biopsy methods. The sample is then analyzed using advanced imaging and 3D analysis technology to detect abnormal cell changes that could indicate the presence of pre-cancerous or cancerous cells. The technology has been clinically validated in multiple studies and has received approval from the US Food and Drug Administration (FDA) for use in the United States.
CDx Diagnostics also offers a range of products and services to support cancer screening and diagnosis, including training and education programs, consulting services, and clinical support tools. The company is committed to improving patient outcomes by providing healthcare professionals with innovative tools and technologies that enable earlier and more accurate detection of cancer.
The company is headquartered in Suffern, New York, and has a global network of partners and distributors to support its products and services.